1. Oral anti‐CD3 immunotherapy for HCV‐nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase‐2a placebo‐controlled trial. Issue 8 (21st November 2014) Authors: Halota, W.; Ferenci, P.; Kozielewicz, D.; Dybowska, D.; Lisovoder, N.; Samira, S.; Shalit, I.; Ellis, R.; Ilan, Y. Journal: Journal of viral hepatitis Issue: Volume 22:Issue 8(2015) Page Start: 651 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗